Navigation Links
Avid Bioservices Presents Data From Manufacturing Successes Achieved With Single-Use Bioreactor Systems

TUSTIN and SAN DIEGO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Avid Bioservices, Inc. today reported that it presented data from several antibody projects using the company's recently installed Single-Use Bioreactors (S.U.B.) at the Thermo Scientific BioProduction Optimization Workshop held this week in San Diego, California. In response to growing demand for its cGMP bioproduction services, Avid installed a HyClone 1000 L S.U.B. in its manufacturing suite in November 2008, complementing the HyClone 100 L S.U.B. that was already installed in Avid's Process Development unit at its production facilities in Tustin, California.

At the workshop, Avid researchers discussed their early successes using the 100 L S.U.B. and 1000 L S.U.B. systems. Avid senior vice president of bioprocess development and manufacturing Richard Richieri presented data on cell culture performance at both the 100 L and 1000 L scale, demonstrating that the process is scalable and that cell growth and production are very similar in the two systems. Avid's initial analysis of the antibody product also shows excellent comparability between these disposable units and traditional reactors.

"We installed our HyClone S.U.B. systems to help meet the rising demand for our biomanufacturing services," said Mr. Richieri. "Our experience to date with these systems has been very positive, and we welcomed the opportunity to share our insights at this workshop with other industry representatives. Avid's commitment to efficient production has led us to innovate in a number of areas, including installing our two HyClone S.U.B. systems and acquiring a ClonePix automated system for optimal clone selection. These new technologies have been very successful in reducing our processing costs and shortening project timelines."

The Thermo Scientific HyClone S.U.B. consists of a reusable stainless steel outer support container and S.U.B. BioProcess Container (BPC(R)) that integrates with existing bioreactor control systems, providing the advantages of single-use bioprocessing without having to install a complete new bioreactor system. The retrofit product replaces the stainless steel bioreactor vessel in existing bioreactor systems, making it a flexible, rapid and economic option to increase bioreactor capacity.

Avid Bioservices is a wholly owned subsidiary of Peregrine Pharmaceuticals Inc. (Nasdaq: PPHM).

About Avid Bioservices

Avid Bioservices provides a comprehensive range of cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid manufactures cGMP commercial product, as well as clinical supplies for all phases of clinical trials. The company's comprehensive range of cGMP services includes cell banking, stability testing, clinical product manufacturing and purification, bulk packaging, final product filling and regulatory support. Avid also provides a variety of process development activities, including cell line optimization, analytical method development and product characterization. The company has over 10 years of antibody manufacturing experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes. Avid was recently named the first pre-approved U.S. contract manufacturer of the DSM/Crucell PER.C6(R) production system. For more information about Avid, visit

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

     Avid Bioservices           Media
     Candice Fliedner           GendeLLindheim BioCom Partners
     (714) 508-6188             Barbara Lindheim
                                (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Avid Bioservices Expands Capabilities With Installation of Innovative Thermo Scientific HyClone Single-Use Bioreactor Systems
2. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
3. ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference
4. ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections
5. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
6. The EntreTech Forum Presents... Greening Of America - The Conversion of Bio-Agriculture, Bio-Energy, and Bio-Products to Eco-Sustainable Businesses
7. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
8. ImmunoVaccine Technologies Presents at OneMed Place Finance Forum
9. Medivation Presents New Data on Dimebons Novel Mechanism of Action
10. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
11. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
Post Your Comments:
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... Nov. 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... in a fireside chat discussion at the Piper Jaffray ... . The discussion is scheduled for Wednesday, December ... .  A replay will be available for 14 ... , Julie NormartVP, Corporate Communications and Business Development ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):